Khoja Hamid

Chief Scientific Officer Khoja Hamid bought 30,000 shares of FBLG at $0.38; prior two FBLG buys posted 90-day returns of +1355.5% and +3815.8%

Khoja Hamid purchased 30,000 shares at $0.38, doubling his FBLG holdings from 31,250 to 61,250 shares. His cross-ticker track record shows 2 prior buys with an average 90-day return of +2585.6% and a 100% 90-day win rate, while his two prior buys specifically at FBLG (May 2025 and August 2024) each showed substantial 90-day gains (+1355.5% and +3815.8% respectively), both well-timed. This purchase occurs as the stock trades at $8.38, down 69.6% from its 52-week high of $27.60, yet up 51.1% in the past 30 days and 58.9% over 90 days. The company remains unprofitable with net income of $-5.8M against a market cap of $566.4M, but notably 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. The combination of a historically accurate insider's large relative purchase (+96% to holdings), strong 30/90-day price recovery, and multi-insider buying interest suggests elevated conviction in near-term recovery prospects.

Chief Scientific Officer Hamid buys 20,000 FBLG shares at $0.84, tripling position; stock down -93.7% from $259.20 52-week high.

Khoja Hamid, Chief Scientific Officer, purchased 20,000 shares at $0.84 on 2025-05-27, increasing his holdings from 11,250 to 31,250 shares (+177.8% net change). The transaction occurs while FBLG trades at $16.24, down -93.7% from its 52-week high of $259.20 and down -33.4% over the last 30 days. Critically, the company reported net income of $-5.0M over its most recent full fiscal year, establishing a backdrop of unprofitability. Hamid's prior buy at FBLG on 2024-08-12 generated a 90-day return of +3815.8%, suggesting his prior purchase timing proved well-timed at this ticker; however, that historical pattern does not extend to this current transaction, which has already declined over the trailing 30- and 90-day periods shown in the PRICE data.

CSO Khoja Hamid bought 10,000 shares of FBLG at $1.90; stock now at $36.60, down 93.7% from 52-week high of $582.00.

Chief Scientific Officer Khoja Hamid purchased 10,000 shares at $1.90 on 2024-08-12, increasing his holdings from 1.2K to 11.2K shares. The transaction occurred after severe price deterioration: the stock has declined 93.7% from its 52-week high of $582.00 and fallen 83.8% over the past 90 days. While the company reported net income of $898.0K, this represents a recovery from being unprofitable over its most recent full fiscal year. The sharp downward momentum and historical loss-making status present context for evaluating whether this near-trivial-cost basis ($1.90) reflects an opportunity or risk; the 800% increase in his own holdings relative to his small pre-existing position of 1.2K shares marks the transaction as material to his personal exposure.